BNTX BioNTech SE - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
BNTX Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$115.98
Analyst Target
$140.82
+21.4%
Upside
52W High
$126.77
52W Low
$81.2
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$29.1B
P/E
N/A
ROE
-3.0%
Profit margin
-18.1%
Debt/Equity
0.01
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
65%
Analysis Accuracy
BNTX exhibits a weak Piotroski F-Score of 1/9, signaling significant financial distress based on fundamental accounting metrics. Despite strong revenue growth and robust gross margins, the company is currently unprofitable with negative earnings, declining ROE and ROA, and highly volatile earnings surprises. While the balance sheet shows minimal leverage and strong liquidity, the lack of profitability and inconsistent earnings delivery offset these strengths. Analysts maintain a strong_buy recommendation, but the stock trades at a high valuation relative to peers and fundamentals, warranting caution.
Key Strengths
Strong revenue growth (22.0% YoY), outpacing many biotech peers
Exceptionally high gross margin (82.49%), indicating pricing power and low production costs
Very strong liquidity position with current ratio of 7.12 and quick ratio of 6.89
Minimal leverage with debt/equity of just 0.01, reducing financial risk
Analyst consensus is strong_buy with 19 analysts supporting upside potential
Key Risks
Piotroski F-Score of 1/9 indicates severe financial weakness and poor profitability trends
Negative profit margin (-18.13%) and negative ROE (-3.04%), signaling ongoing losses
Highly volatile and negative earnings surprises, with 3 of last 4 quarters missing estimates
Forward P/E of -38.24 reflects negative earnings expectations, limiting valuation support
Lack of dividend and zero dividend strength (0/100) reduces income appeal
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
34
Weak
30
65
40
35
0
AI Verdict
Mixed outlook with strong growth and balance sheet offset by weak profitability and earnings instability
Key drivers: High revenue growth and gross margin, Exceptional liquidity and low debt, Very weak Piotroski score and negative profitability, Extreme earnings volatility and negative forward earnings
Confidence
70%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 9.23 may be justifiable if growth sustains
Watchpoints
- Forward P/E of -38.24 indicates no earnings support for valuation
- No Graham Number or intrinsic value available due to losses
- Price/book of 1.28 is elevated for a loss-making company
Future
65/100
Ref Growth rates
Positives
- 22.0% YoY revenue growth is strong
- Most recent Q/Q EPS growth of +92.5% shows potential improvement
Watchpoints
- Year-over-year EPS growth is -114.8%, reflecting deep earnings contraction
- Earnings growth highly unpredictable with large negative surprises
Past
40/100
Ref Historical trends
Positives
- History of large earnings beats in prior years (e.g., 2021-2022)
Watchpoints
- Recent quarters show deteriorating performance with 3 of last 4 missing estimates
- Average earnings surprise over last 4 quarters is -69.3%, indicating systemic issues
Health
35/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 7.12 and quick ratio of 6.89 indicate strong short-term liquidity
- Debt/equity of 0.01 shows negligible leverage
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial distress
- ROE of -3.04% and ROA of -2.30% reflect poor asset efficiency
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout history
- Dividend strength score is 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$115.98
Analyst Target
$140.82
Upside/Downside
+21.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BNTX and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BNTX
BioNTech SE
Primary
|
+6.2% | -19.4% | -5.0% | +0.6% | +22.1% | +6.4% |
|
HUM
Humana Inc.
Peer
|
-29.8% | -42.4% | +0.5% | +24.9% | +5.3% | -1.3% |
|
BIIB
Biogen Inc.
Peer
|
-37.7% | -41.2% | +19.4% | +30.5% | -2.7% | +4.4% |
|
DXCM
DexCom, Inc.
Peer
|
-31.7% | -50.1% | -22.2% | -32.1% | -11.2% | +5.6% |
|
CNC
Centene Corporation
Peer
|
-27.1% | -40.4% | -27.2% | +63.7% | +17.7% | -1.9% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-38.24
PEG Ratio
N/A
P/B Ratio
1.28
P/S Ratio
9.23
EV/Revenue
4.32
EV/EBITDA
-29.09
Market Cap
$29.1B
Profitability
Profit margins and return metrics
Profit Margin
-18.13%
Operating Margin
-2.17%
Gross Margin
82.49%
ROE
-3.04%
ROA
-2.3%
Growth
Revenue and earnings growth rates
Revenue Growth
+22.0%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.01
Low debt
Current Ratio
7.12
Strong
Quick Ratio
6.89
Excellent
Cash/Share
$60.42
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-10
$N/A
2025-11-03
$-0.12
-220.3% surprise
2025-08-04
$-1.6
-13.8% surprise
2025-05-05
$-1.73
+26.3% surprise
Healthcare Sector Comparison
Comparing BNTX against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
Return on Equity (ROE)
-3.04%
This Stock
vs
-52.77%
Sector Avg
-94.2%
(Below Avg)
Profit Margin
-18.13%
This Stock
vs
-20.78%
Sector Avg
-12.7%
(Weaker)
Debt to Equity
0.01
This Stock
vs
6.16
Sector Avg
-99.8%
(Less Debt)
Revenue Growth
22.0%
This Stock
vs
137.39%
Sector Avg
-84.0%
(Slower)
Current Ratio
7.12
This Stock
vs
3.36
Sector Avg
+112.0%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BNTX
BioNTech SE
|
NEUTRAL | $29.1B | - | -3.0% | -18.1% | $115.98 | |
|
HUM
Humana Inc.
|
NEUTRAL | $32.87B | 25.59 | 7.2% | 1.0% | $273.28 | |
|
BIIB
Biogen Inc.
|
NEUTRAL | $25.17B | 15.84 | 9.3% | 16.0% | $171.59 | |
|
DXCM
DexCom, Inc.
|
BULLISH | $23.29B | 32.26 | 30.6% | 16.0% | $58.06 | |
|
CNC
Centene Corporation
|
BEARISH | $22.49B | - | -21.9% | -3.2% | $45.75 |
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
19 analysts
Goldman Sachs
2026-01-16
Neutral
Buy
HC Wainwright & Co.
2025-11-10
Buy
Buy
UBS
2025-11-06
Neutral
Neutral
JP Morgan
2025-10-23
Neutral
Neutral
Morgan Stanley
2025-10-10
Overweight
Overweight
JP Morgan
2025-09-22
Neutral
Neutral
HC Wainwright & Co.
2025-09-08
Buy
Buy
HC Wainwright & Co.
2025-08-14
Buy
Buy
Wells Fargo
2025-08-05
Overweight
Overweight
B of A Securities
2025-08-05
Buy
Buy
Past News Coverage
Recent headlines mentioning BNTX from our newsroom.
Newest → oldest
No matching news yet.